FindTrial
Sign In

Effect of Aparajita tablet against Yashtimadhu tablet in mild cognitive impairment

A double blind randomized controlled trial to assess the efficacy of Aparajita tablet against Yashtimadhu tablet in mild cognitive impairment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/04/041903
Enrollment
20
Registered
2022-04-19
Start date
Unknown
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F068- Other specified mental disorders due to known physiological condition

Interventions

None listed

Sponsors

Anjali A
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a) Diagnosed cases of Mild Cognitive Impairment as per DSM V diagnostic criteria. b) Age between 50-70 years. c) Those willing to give written consent. d) Those whose MMSE Score lies between 19-23. e) Those who diagnosed with Type II Diabetes Mellitus. f) No discrimination of gender, religion and economic status.

Exclusion criteria

Exclusion criteria: a) Subjects who have decline in cognitive functions as a result of trauma, surgery cardiovascular diseases, stroke, thyroid dysfunction, chronic kidney diseases, chronic liver diseases. b) Those having major psychiatric co-morbidities.

Design outcomes

Primary

MeasureTime frame
To compare the efficacies of Apar�?jita cÅ«rÅ?a and Yaṣṭimadhu cÅ«rÅ?a in Mild Cognitive Impairment by using MMSE To compare the Quality of Life of subjects with Mild Cognitive Impairment in study and control groups. Timepoint: Three months—

Secondary

MeasureTime frame
nilTimepoint: nil—

Countries

India

Contacts

Public ContactDr Satheesh K MDAy

VPSV Ayurveda College , Kottakkal

drsatheeshpdm@gmail.com9249993257

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026